Rapport Therapeutics Inc
NASDAQ:RAPP
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Profitability Summary
Rapport Therapeutics Inc's profitability score is 20/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.
Score
We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.
We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.
Score
Score
Margins
Earnings Waterfall
Rapport Therapeutics Inc
Margins Comparison
Rapport Therapeutics Inc Competitors
| Country | Company | Market Cap |
Operating Margin |
Net Margin |
||
|---|---|---|---|---|---|---|
| US |
|
Rapport Therapeutics Inc
NASDAQ:RAPP
|
1.3B USD |
Loading...
|
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
985.1B USD |
Loading...
|
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
554.2B USD |
Loading...
|
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
281B CHF |
Loading...
|
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
217.8B GBP |
Loading...
|
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
224.3B CHF |
Loading...
|
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
281.3B USD |
Loading...
|
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.6T DKK |
Loading...
|
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
150.9B USD |
Loading...
|
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
97.3B EUR |
Loading...
|
Loading...
|
Return on Capital
Return on Capital Comparison
Rapport Therapeutics Inc Competitors
| Country | Company | Market Cap | ROE | ROA | ROCE | ROIC | ||
|---|---|---|---|---|---|---|---|---|
| US |
|
Rapport Therapeutics Inc
NASDAQ:RAPP
|
1.3B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
985.1B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
554.2B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
281B CHF |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
217.8B GBP |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
224.3B CHF |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
281.3B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.6T DKK |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
150.9B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
97.3B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
